Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Peg-G-CSF vs G-CSF in CAG Regimen for AML
NCT03045627Phase 2Unknown
- Sponsor
- Shandong University
- Start
- Jan 2017
- Primary completion
- Jan 2018
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of pegteograstim in acute myeloid leukemia (AML), sponsored by Shandong University. Primary endpoint: Complete Remission at 60 days. Status: unknown.
02
Drugs
pegteograstim
03
Conditions
acute myeloid leukemia (AML)
Beyond the preview
Go deeper on NCT03045627.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03045627.